Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

JSPR

Jasper Therapeutics Inc

May 13 • 04:00PM ET

20.76

Dollar change -0.57
Percentage change -2.67	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.41	Insider Own	22.27%	Shs Outstand	15.09M	Perf Week	-7.49%
Market Cap	313.27M	Forward P/E	-	EPS next Y	-4.32	Insider Trans	21.26%	Shs Float	11.73M	Perf Month	-25.11%
Income	-64.47M	PEG	-	EPS next Q	-1.23	Inst Own	43.31%	Short Float	5.24%	Perf Quarter	21.76%
Sales	0.00M	P/S	-	EPS this Y	19.66%	Inst Trans	5.01%	Short Ratio	6.13	Perf Half Y	181.68%
Book/sh	7.03	P/B	2.95	EPS next Y	12.96%	ROA	-89.35%	Short Interest	0.61M	Perf Year	39.33%
Cash/sh	5.76	P/C	3.61	EPS next 5Y	-	ROE	-112.67%	52W Range	4.00 - 31.01	Perf YTD	163.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-80.33%	52W High	-33.05%	Beta	2.22
Dividend TTM	-	Quick Ratio	7.19	Sales past 5Y	0.00%	Gross Margin	-	52W Low	419.00%	ATR (14)	1.94
Dividend Ex-Date	-	Current Ratio	7.19	EPS Y/Y TTM	39.99%	Oper. Margin	0.00%	RSI (14)	38.55	Volatility	8.71% 8.65%
Employees	45	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.12	Target Price	67.00
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-316.56%	Payout	-	Rel Volume	0.35	Prev Close	21.33
Sales Surprise	-	EPS Surprise	6.76%	Sales Q/Q	-	Earnings	Mar 04 BMO	Avg Volume	100.31K	Price	20.76
SMA20	-8.70%	SMA50	-18.14%	SMA200	49.78%	Trades		Volume	35,093	Change	-2.67%

Date	Action	Analyst	Rating Change	Price Target Change
May-06-24	Initiated	H.C. Wainwright	Buy	$65
Apr-03-24	Initiated	Evercore ISI	Outperform	$65
Mar-28-24	Initiated	RBC Capital Mkts	Outperform	$70
Mar-18-24	Initiated	TD Cowen	Outperform
Aug-11-23	Initiated	CapitalOne	Overweight	$7
Feb-28-22	Initiated	Cantor Fitzgerald	Overweight	$10
Nov-08-21	Initiated	Credit Suisse	Outperform	$15
Oct-21-21	Initiated	William Blair	Outperform
Oct-20-21	Initiated	BMO Capital Markets	Outperform	$19
Oct-13-21	Initiated	Oppenheimer	Outperform	$21

Today 08:00AM	Jasper Therapeutics Announces Briquilimab Development Program in Asthma (GlobeNewswire)
May-07-24 04:30PM	Jasper Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire)
12:00PM	Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-02-24 04:30PM	Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.42%
Mar-22-24 08:50AM	Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
04:30PM	Loading…
Mar-21-24 04:30PM	Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) +8.01%
Mar-19-24 08:00AM	Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria (GlobeNewswire) +5.55%
Mar-15-24 08:00AM	New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia (GlobeNewswire)
Mar-14-24 12:00PM	Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know (Zacks) -9.11%
Mar-06-24 12:53PM	JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +8.21%
08:50AM	Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going (Zacks)
Mar-04-24 07:30AM	Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Feb-26-24 04:30PM	Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-23-24 08:00AM	Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire)
Feb-19-24 08:50AM	Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength (Zacks)
08:00AM	Loading…
Feb-07-24 08:00AM	Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference (GlobeNewswire) +18.00%
Feb-06-24 08:59AM	Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock (GlobeNewswire) +14.52%
Feb-05-24 08:00AM	Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire) +7.65%
Feb-02-24 08:00AM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-24 12:14PM	Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why (Zacks)
Jan-05-24 08:30AM	Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones (GlobeNewswire)
Jan-02-24 08:00AM	Jasper Therapeutics, Inc. Announces Reverse Stock Split (GlobeNewswire) -13.74%
Dec-18-23 04:30PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-10-23 11:00AM	Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 (GlobeNewswire)
Nov-30-23 08:00AM	Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Nov-09-23 09:48AM	Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -8.08%
08:00AM	Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-23 04:30PM	Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences (GlobeNewswire)
Nov-02-23 09:00AM	Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023 (GlobeNewswire)
Nov-01-23 08:00AM	Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors (GlobeNewswire)
08:30AM	Loading…
Oct-09-23 08:30AM	Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023 (GlobeNewswire) +16.25%
08:00AM	Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Sep-25-23 08:00AM	Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer (GlobeNewswire) -8.97%
Sep-21-23 08:00AM	Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium (GlobeNewswire)
Sep-15-23 08:00AM	Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference (GlobeNewswire) +10.96%
Aug-11-23 04:05PM	Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-04-23 04:51PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-02-23 08:00AM	Jasper Therapeutics Strengthens Management Team with Key Appointments (GlobeNewswire)
Jun-22-23 08:00AM	Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome (GlobeNewswire)
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire)
Jun-13-23 08:00AM	Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer (GlobeNewswire) +6.17%
May-12-23 04:05PM	Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) +5.37%
May-10-23 08:00AM	Jasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board (GlobeNewswire)
Apr-13-23 08:00AM	Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources (GlobeNewswire)
Apr-10-23 04:05PM	Jasper Therapeutics Appoints David Hinds as Senior Vice President, Development Operations (GlobeNewswire)
Mar-31-23 08:00AM	Jasper Therapeutics to Present at Cantor Fitzgeralds The Future of Oncology Virtual Symposium (GlobeNewswire)
Mar-23-23 08:00AM	Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer (GlobeNewswire)
Mar-09-23 08:00AM	Jasper Therapeutics to Present at Upcoming Conferences (GlobeNewswire) -7.00%
Mar-08-23 04:05PM	Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-17-23 08:20AM	Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors (GlobeNewswire)
08:10AM	Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR (GlobeNewswire)
08:00AM	Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR (GlobeNewswire)
Feb-16-23 04:05PM	Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients (GlobeNewswire)
Feb-03-23 04:05PM	Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.43%
Jan-30-23 08:00AM	Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023 (GlobeNewswire)
Jan-27-23 01:10PM	Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jan-25-23 08:00AM	Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock (GlobeNewswire) +9.47%
Jan-24-23 04:25PM	Jasper Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -5.59%
Jan-13-23 08:00AM	Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (GlobeNewswire) +7.88%
Jan-10-23 08:00AM	Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases (GlobeNewswire)
Jan-04-23 08:00AM	Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant (GlobeNewswire) -21.90%
Jan-03-23 08:00AM	Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia (GlobeNewswire) +467.41%
Nov-10-22 04:05PM	Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Sep-26-22 08:00AM	Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting (GlobeNewswire)
Sep-23-22 08:00AM	Jasper Therapeutics to Present at Upcoming Conferences (GlobeNewswire) -13.49%
Sep-15-22 08:00AM	Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant (GlobeNewswire)
Aug-12-22 04:05PM	Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jun-23-22 04:05PM	Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium (GlobeNewswire) +17.34%
Jun-20-22 10:59AM	Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-07-22 08:00AM	Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference (GlobeNewswire) -5.70%
Jun-06-22 08:00AM	Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022 (GlobeNewswire)
May-27-22 08:00AM	After a record-breaking decade, biotech is discovering what hard times feel like (American City Business Journals)
May-17-22 08:00AM	Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia (GlobeNewswire)
May-12-22 04:05PM	Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-28-22 08:00AM	Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting (GlobeNewswire)
Apr-26-22 04:05PM	Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation (GlobeNewswire)
Apr-22-22 08:00AM	Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies (GlobeNewswire)
Mar-31-22 08:00AM	Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting (GlobeNewswire) +5.97%
Mar-25-22 07:30PM	Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-22 08:30AM	Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team (GlobeNewswire)
Mar-18-22 04:05PM	Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-10-22 08:00AM	Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) -7.96%
Feb-28-22 08:00AM	Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer (GlobeNewswire)
Feb-24-22 05:19PM	Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-02-22 01:38PM	Grace Capital Buys Vanguard Consumer Discretionary ETF, Tesla Inc, Jasper Therapeutics Inc, ... (GuruFocus.com) -12.07%
Dec-08-21 11:15AM	Billionaire Ken Griffin Goes Big on These 3 Strong Buy Stocks (TipRanks) +6.00%
08:30AM	Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-20-21 08:21AM	Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth (Simply Wall St.)
Nov-12-21 04:05PM	Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-21 08:00AM	Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy (GlobeNewswire)
Nov-08-21 08:00AM	Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference (GlobeNewswire)
Oct-15-21 09:39PM	Jasper Therapeutics Stock Is up 127% in Three Days. How Much Higher Can It Go? (TipRanks) +31.57%

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mahal Jeetinder Singh	Chief Operating Officer	Mar 12 '24	Option Exercise	7.10	900	6,390	25,909	Mar 12 09:33 PM
Mahal Jeetinder Singh	Chief Operating Officer	Mar 12 '24	Sale	26.44	900	23,792	25,009	Mar 12 09:33 PM
Velan Capital Investment Manag	10% Owner	Feb 08 '24	Buy	12.95	350,000	4,532,500	1,188,500	Feb 09 08:40 PM
Carlyle Group Inc.	Former 10% Owner	Feb 08 '24	Buy	12.95	190,000	2,460,500	1,066,189	Feb 12 06:23 PM
WIGGANS THOMAS G	Director	Nov 28 '23	Buy	0.65	10,000	6,486	50,000	Nov 30 04:05 PM
WIGGANS THOMAS G	Director	Nov 21 '23	Buy	0.64	10,000	6,383	40,000	Nov 22 04:06 PM
WIGGANS THOMAS G	Director	Nov 20 '23	Buy	0.63	10,000	6,309	30,000	Nov 20 08:14 PM
WIGGANS THOMAS G	Director	Nov 17 '23	Buy	0.60	10,000	5,966	20,000	Nov 20 08:14 PM
WIGGANS THOMAS G	Director	Nov 16 '23	Buy	0.60	10,000	5,965	10,000	Nov 20 08:14 PM
Lis William	Director	Oct 13 '23	Sale	0.85	7,965	6,777	53,521	Oct 13 06:56 PM
Mahal Jeetinder Singh	See Remarks	Jun 13 '23	Option Exercise	0.71	9,000	6,390	296,223	Jun 13 08:54 PM
Mahal Jeetinder Singh	See Remarks	Jun 13 '23	Sale	1.66	9,000	14,915	287,223	Jun 13 08:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JSPR

Jasper Therapeutics Inc

Upgrade your FINVIZ experience